rh IGF-1 (mecasermin)
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Disorders
Conditions
Growth Disorders
Trial Timeline
Nov 1, 2005 → Mar 1, 2010
NCT ID
NCT00330668About rh IGF-1 (mecasermin)
rh IGF-1 (mecasermin) is a phase 3 stage product being developed by Ipsen for Growth Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT00330668. Target conditions include Growth Disorders.
What happened to similar drugs?
7 of 20 similar drugs in Growth Disorders were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00330668 | Phase 3 | Terminated |
Competing Products
20 competing products in Growth Disorders